-+ 0.00%
-+ 0.00%
-+ 0.00%
Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026
Share
Listen to the news

Phase 1 data presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, showed deep and durable responses in patients with FGFR3-altered urothelial cancer (UC) and head and neck squamous cell carcinoma (HNSCC). As of the data cutoff in the ongoing study, 6 of 10 evaluable patients with FGFR3 activating alterations treated at doses of ≥3.3 mg/kg had responded, including 3 of 5 with UC and 3 of 3 with HPV-positive HNSCC.

  • Responders to BHV-1530 in UC included patients who failed prior enfortumab vedotin plus pembrolizumab (EV+P) and oral FGFR tyrosine kinase inhibitors. All responders remained on treatment at data cutoff, some beyond 6 months.
     
  • BHV-1530 was well tolerated with no FGFR class toxicities: no DLTs, treatment-related SAEs or deaths, and no ILD; no hyperphosphatemia, nail dystrophy or central serous retinopathy.
     
  • Biohaven completed FDA Type C meeting in 4Q 2026 and plans to initiate a pivotal study evaluating BHV-1530 in FGFR3-altered tumors, starting with UC, expected to begin as early as 1H 2027 to support potential accelerated approval.

BARCELONA, Spain and NEW HAVEN, Conn., Nov. 19, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced clinical data from the ongoing Phase 1 study of BHV-1530, its first in class potential FGFR3-directed antibody-drug conjugate (ADC) with a novel topoisomerase I (TopoIx) payload. The data were presented today by Gerald S. Falchook, M.D., Director of Sarah Cannon Research Institute at HCA HealthONE, in an oral presentation during Plenary Session 3 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain. As of the October 19, 2026 data cutoff, 30 patients had received BHV-1530 monotherapy every three weeks (Q3W) at doses from 1.0 to 12.0 mg/kg, and dose escalation is ongoing. Patients had received a median of two prior lines of therapy for advanced disease, and all patients with UC had progressed on EV+P.

Among 10 efficacy-evaluable patients with activating FGFR3 alterations, treated with BHV-1530 at doses of 3.3 mg/kg or higher, 9/10 had a tumor reduction and 6 achieved a partial response (PR; confirmed or unconfirmed, by investigator assessment per RECIST v1.1; Figure 1). Responses were observed in tumors with FGFR3 mutations and fusions, including in 3 of 5 patients with UC and all 3 patients with HPV-positive HNSCC. All responders remained on treatment as of the data cutoff, some for more than 6 months.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending